CPI to Showcase Results of Biologic Drug Development Collaboration

Published on: 

Centre for Process Innovation (CPI) is set to host an event in Darlington, UK, on June 26, 2019 to showcase the results of a £11.2-million (US$14.03-million) collaborative project to optimize biotherapeutic development.

Centre for Process Innovation (CPI), a UK-based technology innovation centerand a founding member of the High Value Manufacturing Catapult, announced on June 17, 2019 that it will host an event in Darlington, UK, on June 26, 2019 to publicize the results of the £11.2-million (US$14.03-million) BioStreamline project to optimize biotherapeutic development.

During the event, the six project partners-Lonza Biologics, UCB Celltech, Sphere Fluidics, Horizon Discovery Group plc (Horizon), Alcyomics, and CPI-will showcase the results and discuss the potential impact on overcoming significant shortcomings of the biologics supply chain.

According to CPI, the biopharmaceutical industry requires a more efficient supply chain that enables it to make predictions about the problems associated with developing novel biotherapeutics and to help reduce the risk and cost of commercialization. This has the potential to offer patients access to a wider range of affordable and effective drugs by limiting the amount of resources wasted on unsuitable molecules. The BioStreamline project mitigates these biotherapeutic development challenges, offering an approach that uses state-of-the-art technologies to provide developers with a better understanding of candidate molecules earlier in the development process. The outputs of the BioStreamline project are expected to allow developers to make better informed decisions about which molecules to progress.

BioStreamline is a collaborative project that brings together complementary assets and expertise from organizations across the spectrum of drug discovery and development with funding from the UK Government’s Advanced Manufacturing Supply Chain Initiative (AMSCI).


The project involved the following major areas:

  • The development of Sphere Fluidics’ novel single-cell analysis and monoclonality assurance system (Cyto-Mine)and associated methodologies. This enables the screening and isolation of rare B cells for antibody discovery and high-expressing single cells for cell-line development, helping to increase the speed and efficiency of entry into the biologics supply chain. 

  • Investigating new approaches to cell-line development by using Horizon’s CRISPR gene editing expertise to create cell lines that display specific phenotypes, including increased productivity.

  • Collecting developability data derived from an initial set of over 200 monoclonal antibody (mAb) sequences, down-selected to a defined panel of 50+ mAbs. These antibodies are produced, purified, and analyzed, and biochemical, biophysical, and stability data on the molecules collected, which is then used together with other inputs to create a flexible and improved approach to biotherapeutics developability.

  • Preclinical assessment of the immunogenicity risks of biotherapeutics to minimize exposure of human patients to potential safety risks during early clinical trial development. 

“We are very excited by the success of the project and feel that a similar approach could be used with other therapeutics, such as viral vectors, which are rapidly emerging as major therapeutic areas,” said John Liddell, chief technologist, CPI, in a press release. “The level of investment that AMSCI has made to this area has provided sufficient breadth of scope to increase understanding of this important aspect of biotherapeutic development, and we are looking forward to presenting the outcomes at the event later this month.”

Source: CPI